Home

About Us

Service

Management

FAQ

Contact Us

Japanese

►"Sound source separation system and acoustic signal acquisition device"
Dr. Tetsuji Ogawa
Assistant Professor Waseda institute for Advanced Study

This invention provides a sound source separation system, a sound source separation method, and an acoustic signal acquisition device capable of accurately separating a target sound from an interfering sound coming from an arbitrary direction, and reducing the device size. The sound separation system includes two microphones, target sound dominant signal generation means for emphasizing a target sound by using microphone observations, target sound inferior signal generation means suppressing the target sound by using microphone observations, and separation means for separating the target sound from the interfering sound by using a spectrum of the target sound dominant signal and a spectrum of the target sound inferior signal.

►"Multiplexed pneumatic Valve Control System for Micro Total Analysis Systems"
Mr. Kentaro Kawai
Research Associates, Faculty of Science and Engineering

This method can control (2n) valve matrix with (2n+2) control pressure lines. This method consists of the pressure inputs of a drive line, a gate line and selective lines as shown in Figure 1. The drive line is used to switch the state of the on-chip valves. The gate line applies the pneumatic pressure of gate valves that select the on-chip valve to activate. The multiplexed selective lines choose one gate valve of the addressed on-chip valve. Figure 2 shows the three steps pneumatic pressure control for changing one valve state. The gate valve is closed by applying the pressure to the gate line for keeping the state of the on-chip valve.  

►Beating Heart Simulator for OPCAB training "BEAT-S1"
Dr. Park Young Kwang
Integrative Bioscience and Biomedical Engineering
CEO, EBM Corporation　

This technology focuses on the development of self-training system for surgical operation and quantitative evaluation of the surgical skills. Our group has developed a self-training system for anastomotic technique in Coronary Artery Bypass Grafting (CABG) to contribute the education of cardiovascular surgery without a risk to patients. The self-training system consists of following portions, 1) “YOUCAN”, coronary and graft vascular silicone model, 2) “BEAT”, a device, simulating stabilized myocardial surface, and 3) Quantitative evaluation system based on in vitro mock circulatory system. This BEAT system comes with innovative SmartBEAT technology using special shape-memory metal to reproduce stabilized heart beating motion.

►"PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt"
Mr. Tatsuya Kawase, Biological Science and Technology

p53 and Akt are critical players regulating tumorigenesis with opposite effects: While p53 transactivates target genes to exert its function as a tumor suppressor, Akt phosphorylates its substrates and transduces downstream survival signals. We identify PHLDA3 as a p53 target gene, which encodes a PH domain only protein. We find that PHLDA3 competes with the PH domain of Akt for binding of membrane lipids, thereby inhibiting Akt translocation to the cellular membrane and activation. In addition, loss of the PHLDA3 genomic locus was frequently observed in primary lung cancers.  These results suggest that PHLDA3 protein may work as an antitumor drug and is a potential biomarker for cancer diagnosis.

►"Research and development of sulfolipid, SQAG for anti-tumor drug and radio-sensitizer."
Mr. Keisuke Ota, Science and Engineering

SQAG effects on the human transplanted tumor in mice by mono-therapy or with radiotherapy. In the experiment of radiotherapy, this compound showed radio-sensitizing activity at the 1/10~1/28 lower dose than mono-therapy, on several types of tumor ( i.e. lung adenocarcinoma, esophageal squamous cell carcinoma, colon adenocarcinoma, and so on). Moreover, it is striking that these compound showed little side-effect , and no genetic toxicity. Therefore, we are developing this promising anti-tumor agent for the clinical usage in the near future.